Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REEM H GHALIB

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1558337782
CMS profile
25140
Location
ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,495.98

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,102.41 4
Food and Beverage $393.57 10

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REEM H GHALIB

NPI 1558337782 · CMS profile ID 25140

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ARLINGTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558337782?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REEM H GHALIB, NPI 1558337782, CMS profile ID 25140. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558337782?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). REEM H GHALIB, NPI 1558337782, CMS profile ID 25140. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558337782?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
REEM H GHALIB, NPI 1558337782, CMS profile ID 25140, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1558337782?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $1,495.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $26.8311/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135362344 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.2911/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153747958 CMS
Fresenius Kabi USA, LLC $26.7607/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146958919 CMS
Janssen Biotech, Inc. $17.5907/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078682922 CMS
Merck Sharp & Dohme LLC $64.9905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764613 CMS
Merck Sharp & Dohme LLC $27.7405/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141888605 CMS
Merck Sharp & Dohme LLC $39.9805/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141889486 CMS
Merck Sharp & Dohme LLC $180.9305/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764605 CMS
Merck Sharp & Dohme LLC $280.6205/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764611 CMS
Merck Sharp & Dohme LLC $115.6805/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764615 CMS
Merck Sharp & Dohme LLC $98.7305/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764749 CMS
Merck Sharp & Dohme LLC $542.1305/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141764767 CMS
ABBVIE INC. $15.6905/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103791799 CMS
Lilly USA, LLC $34.0201/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135381711 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21.29 1
PY2020 $20.65 1
PY2021 $46.95 3
PY2024 $1,495.98 14
PY2025 $3,750.18 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $336,955.82 118
PY2024 Principal investigator $109,074.86 23
PY2023 Principal investigator $199,670.85 30
PY2022 Principal investigator $179,855.97 19
PY2021 Principal investigator $397,738.75 463
PY2020 Principal investigator $682,337.38 146
PY2019 Principal investigator $775,822.80 163

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,396.81 12/07/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612621
Principal investigator 1 Intercept Pharmaceuticals, Inc. $525.03 11/02/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 951612633
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,690.00 09/14/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612601
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,690.00 09/14/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612619
Principal investigator 1 Intercept Pharmaceuticals, Inc. $17,295.00 08/17/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 951612625
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,484.31 08/10/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612603
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,725.60 07/20/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612613
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $104,080.74 07/13/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 949200501
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,400.90 06/22/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612605
Principal investigator 1 Intercept Pharmaceuticals, Inc. $8,506.43 06/22/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 951612623
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,345.00 05/18/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612611
Principal investigator 1 Intercept Pharmaceuticals, Inc. $6,450.00 04/20/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612607
Principal investigator 1 Intercept Pharmaceuticals, Inc. $5.85 03/23/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612609
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,745.90 02/16/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) No dispute reported 06/30/2026 951612615
Principal investigator 1 Intercept Pharmaceuticals, Inc. $1,752.66 02/16/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 951612627
Principal investigator 1 AstraZeneca UK Limited $8,266.47 01/20/2022 Non-covered Recipient Entity
NORTH TEXAS RESEARCH INSTITUTE
AZD2693, Cardiovascular, Renal and Metabolism No dispute reported 06/30/2026 914601197
Principal investigator 1 Intercept Pharmaceuticals, Inc. $500.01 01/19/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) No dispute reported 06/30/2026 951612629
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $4,620.74 01/01/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE LLC
POCC in NASH No dispute reported 06/30/2026 965112085
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,374.52 01/01/2022 Non-covered Recipient Entity
TEXAS CLINICAL RESEARCH INSTITUTE
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO No dispute reported 06/30/2026 909419875